260 related articles for article (PubMed ID: 33102389)
1. Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review.
Chung JS; Morgan TM; Hong SK
Prostate Int; 2020 Sep; 8(3):99-106. PubMed ID: 33102389
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163
[TBL] [Abstract][Full Text] [Related]
3. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
5. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
6. Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
Cussenot O; Cancel-Tassin G; Rao SR; Woodcock DJ; Lamb AD; Mills IG; Hamdy FC
BJU Int; 2023 Nov; 132(5):472-484. PubMed ID: 37410655
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
Loeb S; Giri VN
Eur Urol Oncol; 2021 Feb; 4(1):1-9. PubMed ID: 33390340
[TBL] [Abstract][Full Text] [Related]
10. [DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology].
Ploussard G; Beauval JB; Mathieu R; Barret E; Brureau L; Créhange G; Dariane C; Fiard G; Gauthé M; Renard-Penna R; Ruffion A; Sargos P; Rouprêt M; Roubaud G; Fromont G
Prog Urol; 2022 Mar; 32(3):155-164. PubMed ID: 35125317
[TBL] [Abstract][Full Text] [Related]
11. Relevance of DNA damage repair in the management of prostate cancer.
Banks P; Xu W; Murphy D; James P; Sandhu S
Curr Probl Cancer; 2017; 41(4):287-301. PubMed ID: 28712484
[TBL] [Abstract][Full Text] [Related]
12. New markers in prostate cancer: Genomics.
Fuessel S; Wirth MP
Arch Esp Urol; 2019 Mar; 72(2):116-125. PubMed ID: 30855012
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
15. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer.
Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
[TBL] [Abstract][Full Text] [Related]
16. Sequencing Treatment for Castration-Resistant Prostate Cancer.
Handy CE; Antonarakis ES
Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies for DNA repair-deficient prostate cancer.
Teply BA; Antonarakis ES
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of genetic aberrations in metastatic prostate cancer.
Reichert ZR; McKay RR
Curr Opin Urol; 2019 Jul; 29(4):319-325. PubMed ID: 31158106
[TBL] [Abstract][Full Text] [Related]
19. Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.
Modena A; Iacovelli R; Scarpa A; Brunelli M; Ciccarese C; Fantinel E; Bimbatti D; Massari F; Martignoni G; Tortora G
Target Oncol; 2016 Oct; 11(5):569-577. PubMed ID: 27402433
[TBL] [Abstract][Full Text] [Related]
20. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
